Oppenheimer analyst Mark Breidenbach maintained a Buy rating on Arvinas Holding Company (NASDAQ:ARVN) on Monday, setting a price target of $100, which is approximately 10.38% above the present share price of $90.6.
Breidenbach expects Arvinas Holding Company to post earnings per share (EPS) of -$0.79 for the first quarter of 2021.
The current consensus among 9 TipRanks analysts is for a Strong Buy rating of shares in Arvinas Holding Company, with an average price target of $110.78.
The analysts price targets range from a high of $129 to a low of $93.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $7.6 million and a net profit of -$31.75 million. The company's market cap is $4.29 billion.
According to TipRanks.com, Oppenheimer analyst Mark Breidenbach is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 24.9% and a 51.34% success rate.
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110 and ARV-471. The company was founded in February 2013 and is headquartered in New Haven, CT.